Argenica Therapeutics to Host Investor Webinar on Phase 2 Stroke Trial Progress

Argenica Therapeutics Ltd ( (AU:AGN) ) has issued an announcement.

Argenica Therapeutics Ltd announced an upcoming investor webinar where CEO Dr. Liz Dallimore will discuss the company’s progress, particularly focusing on the Phase 2 Clinical Trial for Acute Ischaemic Stroke. This event signifies an important step in Argenica’s efforts to advance their neuroprotective peptide, ARG-007, potentially impacting the treatment landscape for stroke and other neurological conditions.

The most recent analyst rating on (AU:AGN) stock is a Buy with a A$1.14 price target. To see the full list of analyst forecasts on Argenica Therapeutics Ltd stock, see the AU:AGN Stock Forecast page.

More about Argenica Therapeutics Ltd

Argenica Therapeutics Ltd is a company focused on developing novel therapeutics aimed at reducing brain tissue death following strokes and other brain injuries, as well as neurodegenerative diseases. Their lead product, ARG-007, has shown promise in improving outcomes in pre-clinical models of stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy. The company has completed a Phase 1 clinical trial to assess the safety of ARG-007 and is currently conducting a Phase 2 trial in ischaemic stroke patients.

Average Trading Volume: 108,624

Technical Sentiment Signal: Buy

Learn more about AGN stock on TipRanks’ Stock Analysis page.